{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:54Z","timestamp":1793155794286,"version":"4.5.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasis is a prototypical chronic inflammatory skin disease that illustrates fundamental interactions between innate and adaptive immune pathways. Central to its pathophysiology is the interleukin-23\/interleukin-17 (IL-23\/IL-17) axis, which is driven by both adaptive T helper 17 (Th17) cells and group 3 innate lymphoid cells (ILC3s). These cell populations share the ability to produce IL-17A, IL-17F, and IL-22, cytokines that activate keratinocytes, promote epidermal hyperproliferation, and sustain the inflammatory microenvironment characteristic of psoriatic lesions. While Th17 cells arise from antigen-driven adaptive immune responses and contribute to the persistence of chronic inflammation, ILC3s respond rapidly to cytokine signals such as IL-23 and provide an early, antigen-independent source of IL-17 and IL-22. The functional overlap and extensive crosstalk between these two cell types create a robust and self-amplifying inflammatory circuit. Increasing evidence suggests that psoriasis comprises immunological endotypes in which either Th17 cells or ILC3s may predominate, potentially contributing to clinical heterogeneity and differential responses to targeted therapies. Because psoriasis exemplifies the cooperation between innate and adaptive IL-17-producing lymphocytes, it provides a valuable model for understanding immune regulation in chronic inflammatory and autoimmune diseases. Elucidating the balance, redundancy, and plasticity between Th17 cells and ILC3s may therefore help refine disease stratification and guide future precision-based therapeutic strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1880068","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:24:26Z","timestamp":1782966266000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["T helper 17 cells and group 3 innate lymphoid cells define a spectrum of psoriasis endotypes"],"prefix":"10.3389","volume":"17","author":[{"given":"Michael P.","family":"Sch\u00f6n","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, University Medical Center G\u00f6ttingen","place":["G\u00f6ttingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"aaaaa Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01323","article-title":"The interleukin-23\/-interleukin-17 axis links adaptive and innate immunity in psoriasis","volume":"9","author":"Sch\u00f6n","year":"2018","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03188-w","article-title":"Skin-resident innate lymphoid cells converge on a pathogenic effector state","volume":"592","author":"Bielecki","year":"2021","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042021","article-title":"Understanding type 3 innate lymphoid cells and crosstalk with the microbiota: A skin connection","volume":"25","author":"To","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01296","article-title":"Innate lymphoid cells in intestinal inflammation","volume":"8","author":"Geremia","year":"2017","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.621956","article-title":"Major role of the IL17\/23 axis in psoriasis supports the development of new targeted therapies","volume":"12","author":"Bugaut","year":"2021","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mucimm.2023.01.001","article-title":"CD200R1 promotes interleukin-17 production by group 3 innate lymphoid cells by enhancing signal transducer and activator of transcription 3 activation","volume":"16","author":"Linley","year":"2023","journal-title":"Mucosal Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15033","article-title":"Current developments and perspectives in psoriasis","volume":"21","author":"Sch\u00f6n","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.04.034","article-title":"Animal models of psoriasis-highlights and drawbacks","volume":"147","author":"Sch\u00f6n","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2023.02.006","article-title":"Targeting neutrophil extracellular traps (NETs) ameliorates inflammation in murine psoriasiform dermatitis","volume":"109","author":"Hollstein","year":"2023","journal-title":"J Dermatol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05141-x","article-title":"ILC3s select microbiota-specific regulatory T cells to establish tolerance in the gut","volume":"610","author":"Lyu","year":"2022","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1406908111","article-title":"Activated group 3 innate lymphoid cells promote T-cell-mediated immune responses","volume":"111","author":"von Burg","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/eji.70103","article-title":"The antigen presenting capabilities of group 3 innate lymphoid cells: insights into immunogenic or tolerogenic outcomes for T cells","volume":"55","author":"Calabr\u00f2","year":"2025","journal-title":"Eur J Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1038\/s41467-020-15612-2","article-title":"Microbiota-induced tissue signals regulate ILC3-mediated antigen presentation","volume":"11","author":"Lehmann","year":"2020","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20212391","article-title":"Context-dependent effects of IL-2 rewire immunity into distinct cellular circuits","volume":"219","author":"Whyte","year":"2022","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.70244x","article-title":"S1 guideline: Therapy of generalized pustular psoriasis","author":"M\u00f6\u00dfner","year":"2026","journal-title":"J Dtsch Dermatol Ges"},{"key":"B20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1191782","article-title":"The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases","volume":"14","author":"Navarro-Comp\u00e1n","year":"2023","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585134","article-title":"Interleukin (IL)-12 and IL-18 synergize to promote MAIT cell IL-17A and IL-17F production independently of IL-23 signaling","volume":"11","author":"Cole","year":"2020","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186351","article-title":"TCR-independent functions of Th17 cells mediated by the synergistic actions of cytokines of the IL-12 and IL-1 families","volume":"12","author":"Lee","year":"2017","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2011.07.007","article-title":"Caspase-1-processed IL-1 family cytokines play a vital role in driving innate IL-17","volume":"56","author":"Dungan","year":"2011","journal-title":"Cytokine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1012543","article-title":"The role of inflammasome-derived IL-1 in driving IL-17 responses","volume":"93","author":"Mills","year":"2013","journal-title":"J Leukoc Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601554","article-title":"IL-18 drives ILC3 proliferation and promotes IL-22 production via NF-\u03baB","volume":"199","author":"Victor","year":"2017","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20170369","article-title":"STAT-3-independent production of IL-17 by mouse innate-like \u03b1\u03b2 T cells controls ocular infection","volume":"215","author":"St Leger","year":"2018","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242569","article-title":"IL-17-producing g\u03b4 T cells and innate lymphoid cells","volume":"42","author":"Sutton","year":"2012","journal-title":"Eur J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41590-019-0423-0","article-title":"C-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies","volume":"20","author":"Bernink","year":"2019","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186455","article-title":"Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies","volume":"14","author":"Brembilla","year":"2023","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab617","article-title":"IL-23 and axial disease: do they come together","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715510","article-title":"Targeting the interleukin-23\/interleukin-17 inflammatory pathway: Successes and failures in the treatment of axial spondyloarthritis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.623874","article-title":"IL-23 inhibition in ankylosing spondylitis: where did it go wrong","volume":"11","author":"Baeten","year":"2021","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.818413","article-title":"No significant effects of IL-23 on initiating and perpetuating the axial spondyloarthritis: The reasons for the failure of IL-23 inhibitors","volume":"13","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614255","article-title":"Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis","volume":"12","author":"McGonagle","year":"2020","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160258","article-title":"Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a","volume":"213","author":"Cheung","year":"2016","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3523","article-title":"CD1a on Langerhans cells controls inflammatory skin disease","volume":"17","author":"Kim","year":"2016","journal-title":"Nat Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.03.020","article-title":"CD1a and lipids as mediators of T cell activation in the skin","volume":"145","author":"Fahmy","year":"2025","journal-title":"J Invest Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI92217","article-title":"CD1b-autoreactive T cells contribute to hyperlipidemia-induced skin inflammation in mice","volume":"127","author":"Bagchi","year":"2017","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.7.4076","article-title":"Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells","volume":"165","author":"Bonish","year":"2000","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149485","article-title":"Phospholipase activity of acyloxyacyl hydrolase induces IL-22-producing CD1a-autoreactive T cells in individuals with psoriasis","volume":"52","author":"Singh","year":"2022","journal-title":"Eur J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add9232","article-title":"Group a Streptococcus induces CD1a-autoreactive T cells and promotes psoriatic inflammation","volume":"8","author":"Chen","year":"2023","journal-title":"Sci Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.15252\/embr.201642412","article-title":"CD1d-mediated activation of group 3 innate lymphoid cells drives IL-22 production","volume":"18","author":"Saez de Guinoa","year":"2017","journal-title":"EMBO Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/febs.17014","article-title":"The crosstalk between ILC3s and adaptive immunity in diseases","volume":"291","author":"Wang","year":"2024","journal-title":"FEBS J"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110051","article-title":"ILC3s control airway inflammation by limiting T cell responses to allergens and microbes","volume":"37","author":"Teng","year":"2021","journal-title":"Cell Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41467-020-15695-x","article-title":"Cytokines regulate the antigen-presenting characteristics of human circulating and tissue-resident intestinal ILCs","volume":"11","author":"Rao","year":"2020","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.146","article-title":"Composition of innate lymphoid cell subsets in the human skin: Enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients","volume":"134","author":"Teunissen","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.12.024","article-title":"Unopposed IL-36 activity promotes clonal CD4+ T-cell responses with IL-17A production in generalized pustular psoriasis","volume":"138","author":"Arakawa","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jid.2022.05.1094","article-title":"Comparison of the inflammatory circuits in psoriasis vulgaris, non\u2013pustular palmoplantar psoriasis, and palmoplantar pustular psoriasis","volume":"143","author":"Wang","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8065147","article-title":"Association of pathogenic Th17 cells with the disease severity and its potential implication for biological treatment selection in psoriasis patients","volume":"2020","author":"Aguilar-Flores","year":"2020","journal-title":"Mediators Inflammation"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12658","article-title":"Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin","volume":"170","author":"Dyring-Andersen","year":"2014","journal-title":"Br J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.216","article-title":"A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells","volume":"134","author":"Ward","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00176","article-title":"A human lin CD123 CD127 population endowed with ILC features and migratory capabilities contributes to immunopathological hallmarks of psoriasis","volume":"8","author":"Mora-Velandia","year":"2017","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186604","article-title":"Role of innate immune cells in psoriasis","volume":"21","author":"Sato","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.02.008","article-title":"Streptococcus pyogenes-induced cutaneous lymphocyte antigen-positive T cell-dependent epidermal cell activation triggers TH17 responses in patients with guttate psoriasis","volume":"138","author":"Ruiz-Romeu","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2","article-title":"Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis","volume":"151","author":"Moy","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: Classical vs. paradoxical. The yin-yang of TNF and type I interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-1130-2_11","article-title":"Experimental methods for the immunological characterization of paradoxical psoriasis reactions induced by TNF-\u03b1 biologics","volume":"2248","author":"Morelli","year":"2020","journal-title":"Methods Mol Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.05.015","article-title":"Paradoxical psoriasis: an updated review of clinical features, pathogenesis, and treatment options","volume":"144","author":"Maronese","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137018","article-title":"Paradoxical psoriasis in patients receiving therapy with tumor necrosis factor inhibitors: potential pathogenic mechanisms and the role of genetic factors","volume":"25","author":"Costin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217873","article-title":"Paradoxical psoriasis induced by anti-TNF\u03b1 treatment: evaluation of disease-specific clinical and genetic markers","volume":"21","author":"Bucalo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16883","article-title":"Review article: Paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease","volume":"55","author":"Townsend","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.02.008","article-title":"Psoriasis harbors multiple pathogenic type 17 T-cell subsets: selective modulation by risankizumab","volume":"155","author":"Kim","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.02.743","article-title":"New frontiers in psoriatic disease research, part II: Comorbidities and targeted therapies","volume":"141","author":"Yan","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16273","article-title":"The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01390","article-title":"T cell hierarchy in the pathogenesis of psoriasis and associated cardiovascular comorbidities","volume":"9","author":"Casciano","year":"2018","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.04.021","article-title":"Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets","volume":"148","author":"Kim","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250354","article-title":"Single-cell transcriptomics reveals prominent expression of IL-14, IL-18, and IL-32 in psoriasis","volume":"53","author":"Frost","year":"2023","journal-title":"Eur J Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2200530","article-title":"McAm+cd161- Th17 subset expressing CD83 enhances Tc17 response in psoriasis","volume":"210","author":"Maeda","year":"2023","journal-title":"J Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178118","article-title":"Transcriptomic identification of immune-related hubs as candidate predictor biomarkers of therapeutic response in psoriasis","volume":"26","author":"Cant\u00f3","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1326502","article-title":"Deep analysis of skin molecular heterogeneities and their significance on the precise treatment of patients with psoriasis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.04.005","article-title":"Assessment of treatment-relevant immune biomarkers in psoriasis and atopic dermatitis: Toward personalized medicine in dermatology","volume":"143","author":"Mortlock","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14886","article-title":"Early- and late-onset psoriasis: A cross-sectional clinical and immunocytochemical investigation","volume":"175","author":"Theodorakopoulou","year":"2016","journal-title":"Br J Dermatol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/cei.12086","article-title":"Predominance of activated, clonally expanded T helper type 17 cells within the CD4+ T cell population in psoriatic lesions","volume":"173","author":"Lewis","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.017","article-title":"Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis","volume":"77","author":"Cordoro","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/jdv.70084","article-title":"Biologics for treatment of paediatric plaque psoriasis: a systematic review and network meta-analysis","volume":"40","author":"Aljalfan","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-026-01709-x","article-title":"Comparison of the effects and safety of planned limited-time withdrawal versus continuous maintenance of interleukin inhibitors in patients with psoriasis: a systematic review and network meta-analysis","volume":"16","author":"de Sena","year":"2026","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B84","unstructured":"2026"},{"key":"B85","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12016-017-8634-3","article-title":"Unmet needs in the field of psoriasis: pathogenesis and treatment","volume":"55","author":"Boehncke","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26189233","article-title":"Advances in psoriasis research: Decoding immune circuits and developing novel therapies","volume":"26","author":"Wang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00242","article-title":"Innate lymphocytes in psoriasis","volume":"11","author":"Polese","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1880068\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:24:32Z","timestamp":1782966272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1880068\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2026.1880068"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1880068","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1880068"}}